Notices and Reminders
ORA Reminder: Effective October 1st, ORA requires applicants and recipients to use the updated Other Support format to submit with applications, Just-In-Time (JIT) and Research Performance Progress Reports (RPPRs).
Because of the substantial changes and additional information that needs to be included, all Key Personnel on RPPRs are expected to provide Other Support in the updated format for each RPPR, regardless of when Other Support was last submitted for key personnel. Failure to follow the appropriate format on or after October 1st, may delay processing your application/award by the ORA staff.
ORA Reminder: As a friendly reminder, please make sure you are carefully checking PeopleSoft and the budget justification to make sure OU Norman personnel are not included in the OUHSC personnel line. Failure to properly list the OUHSC versus Norman personnel in the budget preparation phase may result in a rebudget request from the sponsor, and could negatively impact processing of the award..
NIH Policy Reminder: NIH awards are made to recipients, which are most often institutions, not individuals. NIH grants-policy staff members conduct official business with the Authorized Organization Representative (AORs), as detailed in NIHGPS Chapter 2.1.2 Recipient Staff. As a reminder, inquiries regarding general grants-policy matters are best directed first to the recipient’s Office of Sponsored Programs; specifically, the AOR. In rare instances where these contacts are not able to assist in resolving the inquiry, or determine a need to seek guidance from the NIH on a complex or unusual policy circumstance, recipient/applicant’s AOR, not the PD/PI, may submit policy-related inquiries on the organization’s behalf to the NIH grants policy inbox. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-151.html
Change to OUHSC new NIH Other Support pages requirements. OUHSC will not start implementing this policy internally until October 01, 2021 (previously July 1, 2021). Please keep in mind, that other institutions may have already implemented this policy and you may be required to use the new format for them before the OUHSC October 01, 2021 date.
Workshops and Seminars
Save the Date - ORA Noon Conference offered via Zoom
Date: September 29, 2021 at 1:00 pm
Topic: Writing Manuscripts
Description: Communicating the results of your research is an important part of the research enterprise. This presentation will cover how to write original articles and provide tools necessary to successfully write, submit, and publish a manuscript. It will introduce the purpose of each section of a research article, describe the recommended approach, and provide
information about common mistakes in writing for biomedical publications. APA’s Journal Article Reporting Standards (JARS) will also be introduced.
Lunch and learn - Patents 101
Date: September 29, 2021, 12:00 pm
Description: First Do No Harm - How To Write and Speak about Your Invention Without Losing U.S. or Foreign Patent Rights.
We invite you to join us for an upcoming session of Innovation to Impact, a series of lunch discussions for faculty, staff and graduate students about the creation, management and commercialization of intellectual property (IP). This month's speaker is Chris Corbett, Director of Intellectual Property at OTD.
Join Zoom Meeting: https://oklahoma.zoom.us/j/92107292183?pwd=YzhCeG1sV0R2UlYxcndJK1lvUk1UUT09
Harold Hamm Diabetes Center (HHDC) Research Symposium CALL FOR ABSTRACTS
Deadline for abstracts: October 1, 2021
Abstracts must be received by 5 p.m. HHDC 2021 Research Symposium will be held VIRTUALLY on Friday, November 12, 2021. The Symposium will consist of selected oral presentations by faculty and Symposia talks by UTPAL PAJVANI, M.D., Ph.D., Associate Professor of Medicine, Columbia University, LORI SUSSEL, Ph.D., Professor of Medicine, University of Colorado Denver – Anschutz Medical Campus and KENT THORNBURG, Ph.D., Professor of Medicine, Oregon Health & Science University.
Additional details: https://www.ouhealth.com/harold-hamm-diabetes-center/diabetes-research/diabetes-lectures-seminars-visiting-professorshi/diabetes-research-symposium/
NSF 2021 Fall Virtual Grants Conference
Date: October 4-8, 2021
Description: NSF has announced the 2021 Fall Virtual Grants Conference to be held October 4-8, 2021. For those who cannot attend the live conference, all recorded conference sessions will be available on-demand shortly after the event. Just like the in-person grants conferences, the NSF Virtual Grants Conference is a must, especially for new faculty, researchers, and administrators. The event is designed to give new faculty, researchers, and administrators key insights into a wide range of current issues at the National Science Foundation. NSF program officers will be providing up-to-date information about specific funding opportunities and answering attendee questions.
To learn more and to register, visit https://nsfpolicyoutreach.com/fall-21-virtual-conf/.
The Oklahoma Rural Health Conference
Date: October 6-7, 2021, Edmond Conference Center
Description: This two-day event brings together rural health stakeholders to learn from experts in rural health and each other.
Oak Ridge Institute for Science and Education (ORISE)
- Webinar: The Value of Intellectual Property to Your R&D Career
Date: September 21 – 12 to 1 p.m. ET
Abstract: Intellectual property (IP) is a work or invention that is the result of creativity to which an individual or an organization has rights and for which one may apply for a patent, copyright, or a trademark. Over the course of a career in research and development, you may have several opportunities to develop unique IP. Knowing how to take a novel idea forward, how to protect it, and how to leverage your idea into new opportunities can be key elements of your professional development. In this presentation, Dr. Ken Tobin, holder of 15 U.S. patents and co-founder of Hubble Telemedical Inc., will describe his 32-year relationship with IP and provide insight into the inventive process and lessons learned.
- Panel Discussion: Transitioning from a Postdoc to an Early-Career Professional at a Federal Agency
Date: September 23 – 12 to 1 p.m. ET
Abstract: What are the “next steps” in transitioning from a postdoctoral opportunity to an early-career STEM professional at a federal agency? Join our panel of early-career federal STEM staff members as they describe their path from “trainee” to “early career” and answer questions posed by ORISE moderator Dr. Ashley Golden, as well as answer questions from attendees.
OUHSC Funding Opportunities
Presbyterian Health Foundation (PHF) Bridge Grant Program Cycle III Request For Applications
Deadline: November 10, 2021
Description: The primary objective of the PHF Bridge Grant Program is to provide funding to enhance OUHSC faculty competitiveness for extramural funding. OUHSC Principal Investigators are eligible if they meet the following criteria: 1) have submitted an extramural application within the past 18 months that was scored but not funded, 2) are requesting over $750,000 in total direct costs and over $200,000 in total facilities and administration (F&A) costs; and 3) received a review that ranks applications and provides critiques. This program can provide funding for up to $75,000 for one year. Guidelines and Application Form are attached for or can be found here. If you have any questions, please email ORA4PHF@ouhsc.edu
Link to Full Announcement: https://research.ouhsc.edu/Resources/PHF-Funding-2021
Office of Technology Commercialization presents the following opportunities for researchers to engage with industry (click here for more information, or email firstname.lastname@example.org or email@example.com).
- BioMarin is welcoming proposals for developing therapeutics that correct the underlying molecular defect in genetic-based rare diseases with particular interest in platform technologies for genome editing, vector engineering, and new or improved modes of delivery. Out of scope: oncology, infectious disease. Submission entails a 1-pg non-confidential summary of technology (deadline 9/29).
- Johnson & Johnson Innovation is seeking academic expertise and technologies related to the complement pathway which could play a role in systemic inflammatory or neuroinflammatory processes. Targets of interest include: CR1, C3, MASP, and alternate complement pathway targets. Out of scope: C5-C9 and drug repurposing approaches. Submission entails a 1-pg non-confidential summary of technology (deadline 9/30).
- Johnson & Johnson Innovation is seeking technologies focused on the mechanism of exosome uptake in the GI tract with a view of applying this knowledge to the oral delivery of macromolecules. Preference is for technologies with data demonstrating in vitro transport correlates with in vivo transport and any species differences is advantageous. Submission entails a 1-pg non-confidential summary of technology (deadline 10/14).
- A global pharmaceutical company (requested anonymity) is seeking a range of collaboration opportunities for therapeutic targets and/or assets that target myeloid malignancies, specifically AML, MDS, MPN. Specific pathways of interest include pro-apoptotic pathways, epigenetic targets, differentiation of myeloid malignant cells, tumor specific membrane targets, and splicing regulators. Submission entails a 1-pg non-confidential summary of technology (deadline 10/21).
The University of Oklahoma Center for Health Equity
Deadline: October 1, 2021
Description: The goal of this proposed Center of Biomedical Research Excellence (COBRE) is to advance inquiry to address the persistent sources of health and health care inequality in Oklahoma. We seek to build core facilities to support this work and will partner with multiple departments at the University of Oklahoma (Norman Campus and Health Sciences Center) to develop a cadre of researchers pursuing studies in partnership with Oklahoma communities. We are requesting pre-proposals from qualified new investigators (tenure-track faculty without previous R01 funding) who are able to devote 6 months of effort to their proposed research project over a period of 2-3 years beginning in the fall of 2022. It is expected that research project leaders will transition to independent research at the end of their projects, thereby contributing to the ongoing development of research on health equity at the University of Oklahoma’s campuses. Interested candidates should submit a one-page overview (including specific aims) of their proposed research as a PDF file to Paul Spicer (firstname.lastname@example.org) no later than October 1, 2021. Project budgets generally will not exceed $150,000 in direct costs for each year. Selection of the first cohort for the application will be made by October 15 with a draft of the full 6-page application expected by November 15.
NOTE: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted). The letters of intent will be reviewed and a single application will be chosen for submission from the University.
NIH Funding Opportunities
Other Funding Opportunities
The Mselanoma Research Alliance (MRA) 2021-2022 Request for Proposal
Team Science Award Letters of Intent Due: October 6, 2021
Young Investigator Award Eligibility Checklist Due: November 3, 021
Young Investigator and Pilot Awards Full Proposals Due: November 17, 2021
Team Science Award Full Proposals Due (from invited applicants) Due: January 19, 2022
Description: MRA anticipates supporting at least $12.8 million in new funding. Proposals will be accepted for Team Science, Academic-Industry Partnership, Young Investigator, and Pilot Awards. Special Opportunities are also available in immunotherapy, women in research, and patient-centric clinical trials. MRA encourages applications from a diverse pool of investigators. Full descriptions of each award opportunity offered, including all Special Opportunity Awards, as well as eligibility criteria and instructions can be found on the MRA website at CureMelanoma.org/RFP
Proposals should be submitted via the proposalCENTRAL online application tool: https://proposalcentral.com/
NSF Reproducible Cells and Organoids via Directed-Differentiation Encoding (RECODE)
Preliminary Proposals Due: November 22, 2021
Full Proposals Due: March 31, 2022
Link to Full Announcement: https://www.nsf.gov/pubs/2021/nsf21608/nsf21608.htm
NSF Ecology and Evolution of Infectious Diseases (EEID)
Applications Due: November 24, 2021
Link to Full Announcement: https://www.nsf.gov/pubs/2021/nsf21609/nsf21609.htm